Evestra (United States)

Recent papers from Evestra (United States)

1. Endometriosis from Initiation to Innovation: Immune Microenvironments, Clonal Lesion Biology, and the Emerging Therapeutic PipelineCancer Letters · 2026
2. Abstract 5679: LIFR inhibition with EC359 triggers ferroptosis to overcome chemoresistance in endometrial cancer.Cancer Research · 2026
3. Abstract 3110: Targeting LIF/LIFR signaling with EC359 overcomes chemoresistance and enhances chemotherapy efficacy in ovarian cancerCancer Research · 2026
4. EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR SignalingBiomolecules · 2025
5. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancernpj Precision Oncology · 2025
6. Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting FerroptosisCancers · 2025
7. Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast CancerCancers · 2024
8. Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosisnpj Precision Oncology · 2024
9. Abstract 5998: Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosisCancer Research · 2024
10. Abstract 4688: EC359, A new therapeutic drug for the treatment of low grade serous ovarian cancerCancer Research · 2024
11. Abstract 5986: Significance of LIF/LIFR axis in the progression of inflammatory breast cancerCancer Research · 2024
12. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic SignalingInternational Journal of Molecular Sciences · 2023
13. Next step in the development of mesoprogestins: the preclinical profile of EC313Frontiers in Endocrinology · 2023
14. Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer GrowthSHILAP Revista de lepidopterología · 2022
15. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast CancerCancer Research · 2022
16. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancerCommunications Biology · 2021
17. LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancerSHILAP Revista de lepidopterología · 2021
18. Targeting LIF/LIFR signaling in cancerGenes & Diseases · 2021
19. EC330, a small-molecule compound, is a potential novel inhibitor of LIF signalingJournal of Molecular Cell Biology · 2020
20. Controlled-Release from High-Loaded Reservoir-Type Systems—A Case Study of Ethylene-Vinyl Acetate and ProgesteronePharmaceutics · 2020